Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SARS-CoV-2 Bivalent mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Bivalent mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : SARS-CoV-2 Bivalent mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SARS-CoV-2 Bivalent mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Bivalent mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : SARS-CoV-2 Bivalent mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LVRNA021
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : LiveRNA Therapeutics | Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LVRNA021 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 13, 2023
Lead Product(s) : LVRNA021
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : LiveRNA Therapeutics | Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LVRNA009
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : AIM Innovation Biotechnology | Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19
Details : LVRNA009 is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : LVRNA009
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : AIM Innovation Biotechnology | Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SARS-CoV-2 Variant mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants
Details : SARS-CoV-2 Variant mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 31, 2022
Lead Product(s) : SARS-CoV-2 Variant mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LVRNA009
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Public Offering
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 Per H Share
Details : The net proceeds will be used for advancing R&D of vaccine candidates and continuing to enrich vaccine pipeline including LVRNA009, funding the capital expenditure on the construction of new production facilities for new vaccine products.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 05, 2022
Lead Product(s) : LVRNA009
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SARS-CoV-2 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) : SARS-CoV-2 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : COVID-19 Omicron BA.5 mRNA Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : COVID-19 Omicron BA.5 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable